Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Andrew Allen

Gritstone bio, Inc.

Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Sierra Oncology

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Li Lab of Computational Cancer Immunology

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease.With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

Metric
Company Name	Gritstone bio, Inc.	Sierra Oncology	Therini Bio	Li Lab of Computational Cancer Immunology
Symbol	GRTS
MSH ID	COM:GRITSTONEBIO	COM:SIERRAONCOLOGY	COM:THERINIBIO	ORG:LILAB-UTSW
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Biotechnology	Biotechnology
Country	US	GB	US	US
Stage
Employee Count	231
Website	gritstonebio.com	sierraoncology.com	therinibio.com	lilab-utsw.org
LinkedIn	gritstone-bio		therinibio
Founders

Metric
Market Cap	63.26M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.33M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-6.26M
EBITDA	-147.04M
Operating Income	-154.63M
Net Income	-138.49M
EPS	-1.20
Diluted EPS	-1.20
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-2.55
Operating Profit Margin	-59.14
EBITDA Margin	-110.48
Net Profit Margin	-54.61
Return on Equity	-1.47
Return on Assets	-0.78
Return on Capital Employed	-1.00

COM:GRITSTONEBIO

Gritstone bio, Inc.

Last Close

0.03

21/10 20:00

Market Cap

63.26M

Beta: -

Volume Today

55.25M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.89
P/B Ratio	3.53
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	108.27
EV Multiple	0.31

Metric
Days Sales Outstanding	32.08
Days Payables Outstanding	48.43
Days Inventory Outstanding
Operating Cycle	41.87
Cash Conversion Cycle	-5.44
Asset Turnover	0.01

Metric
Operating Cash Flow	-121.65M
Free Cash Flow	-126.22M
Cash Flow to Debt	-2.64
Operating Cash Flow/Sales	-53.83
Free Cash Flow Yield	-0.64

Metric
Cash & Equivalents	65.28M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.77
Debt to Assets	0.51
Current Ratio	3.88
Quick Ratio	2.99

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	3.08
R&D to Revenue	32.25
SG&A to Revenue	7.21